GC said it has signed a joint research and development agreement with Immetas Therapeutics, a U.S.-based pharmaceutical firm, related to mRNA therapeutics for autoimmune diseases.

Through this joint research, both companies will develop autoimmune disease therapeutics using Immetas' unique platform for congenital immunity and chronic inflammation control, along with GC's mRNA therapeutics and lipid nanoparticle (LNP) delivery platform.

"We expect to create significant synergy in the development of therapeutics for autoimmune diseases through the expertise possessed by both companies," GC R&D Division Head Jung Jae-wook said.

Immetas CEO Gene Wang also said, "We anticipate being able to present new types of therapeutic possibilities for autoimmune diseases by utilizing the mRNA platform established by GC."

Meanwhile, Immetas, a biotech venture based in New Jersey, U.S., develops treatments for aging-related cancer and inflammatory diseases by regulating the innate immune system.

The company is developing a new approach to autoimmune disease treatment through inflammation control based on new evidence that aging-related chronic inflammation is a major mechanism inducing autoimmune diseases.